Does LENVATINIB Cause Immune-mediated enterocolitis? 143 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 143 reports of Immune-mediated enterocolitis have been filed in association with LENVATINIB (Lenvima). This represents 0.4% of all adverse event reports for LENVATINIB.
143
Reports of Immune-mediated enterocolitis with LENVATINIB
0.4%
of all LENVATINIB reports
15
Deaths
110
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From LENVATINIB?
Of the 143 reports, 15 (10.5%) resulted in death, 110 (76.9%) required hospitalization, and 12 (8.4%) were considered life-threatening.
Is Immune-mediated enterocolitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 143 reports have been filed with the FAERS database.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
PEMETREXED (129)
BEVACIZUMAB (92)
TREMELIMUMAB\TREMELIMUMAB-ACTL (63)
Which LENVATINIB Alternatives Have Lower Immune-mediated enterocolitis Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE